Endo Health Solutions (ENDP) 8-K 32nd Annual Health Care Conference

Exhibit 99.1

Cowen and Company

32nd Annual Health Care Conference

March 7, 2012

©2012 Endo, Inc. All rights reserved.

1

©2012  Endo Pharmaceuticals, Inc.

2

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995.  Statements including words such as “believes,”

“expects,”

“anticipates,”

“intends,”

“estimates,”

“plan,”

“will,”

“may,”

“look forward,”

“intend,”

“guidance,”

“future”

or similar expressions are forward-looking statements.  Because these

statements reflect our current views, expectations and beliefs concerning future events, these

forward-looking statements involve risks and uncertainties. Investors should note that many

factors,

as

more

fully

described

under

the

caption

“Risk

Factors”

in

our

Form

10-K,

Form

10-Q

and Form 8-K filings with the Securities and Exchange Commission and as otherwise

enumerated herein or therein, could affect our future financial results and could cause our actual

results to differ materially from those expressed in forward-looking statements contained in our

Annual Report on Form 10-K. The forward-looking statements in this presentation are qualified by

these risk factors. These are factors that, individually or in the aggregate, could cause our actual

results to differ materially from expected and historical results. We assume no obligation to

publicly update any forward-looking statements, whether as a result of new information, future

developments or otherwise.

Solutions for 21

st

Century Healthcare

©2012 Endo, Inc. All rights reserved.

3

I.

Our Diversified Business

II.

Growth Drivers

III.

Commitment to Innovation

IV.

2012 Financial Guidance

V.

Summary

4

ACCESS

OUTCOMES

ECONOMICS

Healthcare

Value

©2012 Endo Pharmaceuticals, Inc.

Solid Track Record of Sales Growth

Endo expects to report more than $3 Billion in 2012 sales  

5

Sustaining our Growth

©2012  Endo Pharmaceuticals, Inc.

STRONG CASH FLOW GENERATION  

6

©2012  Endo Pharmaceuticals, Inc.

DIVERSIFIED HEALTHCARE SOLUTIONS COMPANY

7

©2012  Endo Pharmaceuticals, Inc.

93%

7%

Branded Pharmaceuticals

Generics

56%

19%

18%

7%

Branded Pharmaceuticals

Generics

Devices

Services**

Revenue Mix*

Revenue Mix

Endo -

2008

Endo -

2011

Commitment to Innovation

8

Branded

Pharmaceuticals

Medical Devices

Generic

Pharmaceuticals

Generic Development

•

Continually enhancing

existing products

•

Recent advances:

GreenLight™

XPS

Laser Console

MoXy™

Laser Fiber

AdVance™

XP

(OUS)

•

Developing treatments in

new areas

Topas™

sling

Cryotherapy

•

Exploring new emerging

technologies

•

Key Therapeutic Areas

•

Pain

•

Oncology

•

Endocrinology

•

Semi-Virtual R&D Model

•

Global Partnerships

•

Discovery

•

Early Development

•

Development Pipeline

Supplements strong

commercial base growth

©2012  Endo Pharmaceuticals, Inc.

ANDA

Filings

~50 Current

ANDA Reviews

ANDA

Approvals

AVEED™

Long Acting Injectable

Testosterone

BEMA®

Buprenorphine

(Ph. III)

Pain

Urocidin

™

(Ph. III)

Bladder Cancer

Androgen Receptor Antagonist

Castration Resistant Prostate Cancer

(Ph. I)

(NDA)

New Phase III BEMA

®

Buprenorphine

9

•

Complements pain therapeutics portfolio

•

Draws upon existing expertise in the development

and commercialization of opioids

•

Key Financial Terms:

o

$30 million upfront payment to BDSI

o

$150 million in potential milestone payments

o

Contingent on IP, Clinical and Regulatory events

and designated sales levels

o

Tiered royalties on net sales in the U.S.

©2012  Endo Pharmaceuticals, Inc.

2012 Guidance

10

Guidance

Revenue range

$3.15B -

$3.30B

Adjusted diluted EPS range

$5.00 -

$5.20

Reported (GAAP) diluted EPS range

$2.60 -

$2.80

©2012  Endo Pharmaceuticals, Inc.

2012 Value Creation Opportunities

11

•

Successfully

launch

new

formulation

of

Opana®

ER

•

Support the future growth of Qualitest

o

Invest capital to capture growing demand for products

o

Exceed cost synergies assumed at time of Qualitest acquisition

•

Invest in AMS to accelerate growth

o

AMS/Endo pilot program updates in first half 2012

o

Invest in R&D to accelerate advance of new products to market

•

Maximize operating cash flow to pay down debt

o

Expect ~$500M of cumulative debt repayments to be completed by

end of Q1 2012 on our existing Term Loan indebtedness

©2012  Endo Pharmaceuticals, Inc.

©2012 Endo, Inc. All rights reserved.

12

©2012  Endo Pharmaceuticals, Inc.

13

Reconciliation of Non-GAAP Measures

For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s Current Report on Form 8-K filed today with

the Securities and Exchange Commission

Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for the Year Ending

December 31, 2012

Lower End of Range

Upper End of Range

Projected GAAP diluted income per

common share

$2.60

$2.80

Upfront and milestone-related payments to partners

$0.76

$0.76

Amortization of commercial intangible assets and

inventory step-up

$1.89

$1.89

Acquisition and integration costs related to recent

acquisitions.

$0.10

$0.10

Interest expense adjustment for ASC 470-20 and other

treasury items

$0.21

$0.21

Tax effect of pre-tax adjustments at the applicable tax

rates and certain other expected cash tax savings as a

result of recent acquisitions

($0.56)

($0.56)

Diluted adjusted income per common

share guidance

$5.00

$5.20

The company's guidance is being issued based on certain assumptions including:

•Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results

•Includes all completed business development transactions as of March 7, 2012

Cowen and Company

32nd Annual Health Care Conference

March 7, 2012

©2012 Endo, Inc. All rights reserved.

14